Xiao‐Ming Meng
Impact in
- Nephrology top 0.1%
- Chronic Kidney Disease and Diabetes
- Cancer Research top 0.2%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Papers in
-
- Renal and related cancers 24
- TGF-β signaling in diseases 18
- RNA modifications and cancer 18
- Nephrology 49
- Chronic Kidney Disease and Diabetes 31
- Co-authors
- Hui Y. Lan (25 shared papers)David J. Nikolic‐Paterson (5 shared papers)Arthur C.K. Chung (8 shared papers)Jun Li (25 shared papers)Jun Li (58 shared papers)Xiao Ru Huang (9 shared papers)Taotao Ma (37 shared papers)Cheng Huang (54 shared papers)
- Journals
- International Immunopharmacology (17 papers)Frontiers in Pharmacology (13 papers)Toxicology and Applied Pharmacology (9 papers)Clinical Science (7 papers)Molecular Therapy (7 papers)
- Partner nations
- ChinaHong KongUnited States
In The Last Decade
Xiao‐Ming Meng
256 papers receiving 15.7k citations
Xiao‐Ming Meng's Hit Papers
Peers
Comparison fields: 5 of 145
- Nephrology 2.9k
- Cancer Research 3.1k
- Hepatology 943
- Molecular Biology 7.3k
- Immunology 1.7k
Countries citing papers authored by Xiao‐Ming Meng
This map shows the geographic impact of Xiao‐Ming Meng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiao‐Ming Meng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiao‐Ming Meng more than expected).
Fields of papers citing papers by Xiao‐Ming Meng
This network shows the impact of papers produced by Xiao‐Ming Meng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiao‐Ming Meng. The network helps show where Xiao‐Ming Meng may publish in the future.
Co-authors
The 25 scholars most cited alongside Xiao‐Ming Meng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 259 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | TGF-β: the master regulator of fibrosis Hit paper breakdown → | 2016 | 2740 |
| 2 | TGF-β/Smad signaling in renal fibrosis Hit paper breakdown → | 2015 | 589 |
| 3 | Inflammatory processes in renal fibrosis Hit paper breakdown → | 2014 | 582 |
| 4 | 2011 | 491 | |
| 5 | 2011 | 363 | |
| 6 | 2013 | 331 | |
| 7 | 2010 | 324 | |
| 8 | 2013 | 317 | |
| 9 | 2012 | 315 | |
| 10 | 2010 | 298 | |
| 11 | 2016 | 266 | |
| 12 | 2012 | 254 | |
| 13 | 2015 | 201 | |
| 14 | 2017 | 171 | |
| 15 | 2013 | 170 | |
| 16 | 2019 | 159 | |
| 17 | 2011 | 158 | |
| 18 | 2017 | 157 | |
| 19 | 2021 | 147 | |
| 20 | 2022 | 142 |
About Xiao‐Ming Meng
Xiao‐Ming Meng is a scholar working on Molecular Biology, Nephrology, Cancer Research, Epidemiology and Hepatology, having authored 259 papers that have together received 15.9k indexed citations. Recurring topics across this work include Liver physiology and pathology (37 papers), Liver Disease Diagnosis and Treatment (37 papers), Chronic Kidney Disease and Diabetes (31 papers), Renal and related cancers (24 papers), MicroRNA in disease regulation (23 papers), Cancer-related molecular mechanisms research (21 papers), TGF-β signaling in diseases (18 papers) and RNA modifications and cancer (18 papers). The work is most often cited by research in Nephrology (2.9k citations), Cancer Research (3.1k citations), Hepatology (943 citations), Molecular Biology (7.3k citations) and Immunology (1.7k citations). Xiao‐Ming Meng has collaborated with scholars based in China, Hong Kong and United States. Frequent co-authors include Hui Y. Lan, David J. Nikolic‐Paterson, Arthur C.K. Chung, Jun Li, Jun Li, Xiao Ru Huang, Taotao Ma, Cheng Huang, Haiyong Chen and Patrick Ming‐Kuen Tang. Their work appears in journals such as International Immunopharmacology, Frontiers in Pharmacology, Toxicology and Applied Pharmacology, Clinical Science and Molecular Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.